Tenofovir disoproxil fumarate
- PMID: 13130407
- DOI: 10.1086/378068
Tenofovir disoproxil fumarate
Abstract
Tenofovir disoproxil fumarate (tenofovir DF) is a bioavailable prodrug of tenofovir, a potent nucleotide analogue reverse-transcriptase inhibitor with activity against human immunodeficiency virus (HIV) and hepatitis B virus. It is administered as a single 300-mg tablet once daily. It was approved for the treatment of HIV infection on the basis of data from clinical trials demonstrating activity in treatment-experienced patients, and it was subsequently shown to be effective when used as a component of initial therapy. Tenofovir DF is active against some nucleoside-resistant strains of HIV. However, cross-resistance is associated with multiple thymidine analogue mutations that include 41L or 210W. The signature mutation is the K65R mutation, which causes variable loss in susceptibility to tenofovir DF, didanosine, and abacavir. Tenofovir DF has been well tolerated in clinical trials with durations of follow-up up to 96 weeks. It is associated with more-favorable lipid profiles than stavudine and has not been associated with the mitochondrial toxicity attributed to other nucleoside analogues.
Similar articles
-
K65R, TAMs and tenofovir.AIDS Rev. 2004 Jan-Mar;6(1):22-33. AIDS Rev. 2004. PMID: 15168738 Review.
-
Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.J Infect Dis. 2004 Mar 1;189(5):837-46. doi: 10.1086/381784. Epub 2004 Feb 10. J Infect Dis. 2004. PMID: 14976601 Clinical Trial.
-
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.J Infect Dis. 2004 Apr 1;189(7):1185-92. doi: 10.1086/380398. Epub 2004 Mar 12. J Infect Dis. 2004. PMID: 15031786 Clinical Trial.
-
Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.Expert Rev Anti Infect Ther. 2006 Aug;4(4):523-35. doi: 10.1586/14787210.4.4.523. Expert Rev Anti Infect Ther. 2006. PMID: 17009933 Review.
-
Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.Clin Infect Dis. 2008 Apr 15;46(8):1299-309. doi: 10.1086/528863. Clin Infect Dis. 2008. PMID: 18444871
Cited by
-
Recent advances in prevention of hepatitis B recurrence after liver transplantation.World J Gastroenterol. 2015 Jan 21;21(3):829-35. doi: 10.3748/wjg.v21.i3.829. World J Gastroenterol. 2015. PMID: 25624716 Free PMC article. Review.
-
Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases.Clin Mol Hepatol. 2016 Jun;22(2):286-91. doi: 10.3350/cmh.2015.0066. Epub 2016 Jun 30. Clin Mol Hepatol. 2016. PMID: 27377911 Free PMC article.
-
Drug metabolism in drug discovery and development.Acta Pharm Sin B. 2018 Sep;8(5):721-732. doi: 10.1016/j.apsb.2018.04.003. Epub 2018 Apr 12. Acta Pharm Sin B. 2018. PMID: 30245961 Free PMC article. Review.
-
Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity.Toxins (Basel). 2010 Aug;2(8):2055-82. doi: 10.3390/toxins2082055. Epub 2010 Aug 9. Toxins (Basel). 2010. PMID: 22069672 Free PMC article. Review.
-
Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial.PLoS Clin Trials. 2007 May 25;2(5):e27. doi: 10.1371/journal.pctr.0020027. PLoS Clin Trials. 2007. PMID: 17525796 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous